Back to today’s briefing

Story perspectives

FDA Approves Trials for Two Innovative Corneal Treatments

1/11/2026

29 3

Summary

EyeYon Initiates Trials

EyeYon Medical gained FDA approval to begin U.S. first-in-human trial of EndoArt, a synthetic corneal implant for chronic edema, with enrollment set for March 2026.
The trial will be led by Professor Francis Mah and involve ten corneal surgeons to assess safety and long-term performance.
Separately, GenEditBio received FDA approval for an IND to start a Phase 1/2 trial of GEB-101 for TGFBI corneal dystrophy, with enrollment in Q2 2026.

1 of 1

EyeYon Initiates Trials

EyeYon Medical gained FDA approval to begin U.S. first-in-human trial of EndoArt, a synthetic corneal implant for chronic edema, with enrollment set for March 2026.
The trial will be led by Professor Francis Mah and involve ten corneal surgeons to assess safety and long-term performance.
Separately, GenEditBio received FDA approval for an IND to start a Phase 1/2 trial of GEB-101 for TGFBI corneal dystrophy, with enrollment in Q2 2026.